- Home
- VSTM vs ONCY Comparison
VSTM vs ONCY Comparison
Compare VSTM & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- ONCY
- Stock Information
- Founded
- VSTM 2010
- ONCY 1998
- Country
- VSTM United States
- ONCY Canada
- Employees
- VSTM N/A
- ONCY N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- ONCY Pharmaceuticals and Biotechnology
- Sector
- VSTM Health Care
- ONCY Health Care
- Exchange
- VSTM Nasdaq
- ONCY Nasdaq
- Market Cap
- VSTM 425.9M
- ONCY 49.1M
- IPO Year
- VSTM 2012
- ONCY 1999
- Fundamental
- Price
- VSTM $4.85
- ONCY $0.79
- Analyst Decision
- VSTM Strong Buy
- ONCY Strong Buy
- Analyst Count
- VSTM 9
- ONCY 4
- Target Price
- VSTM $12.63
- ONCY $4.33
- AVG Volume (30 Days)
- VSTM 2.4M
- ONCY 1.2M
- Earning Date
- VSTM 08-07-2025
- ONCY 07-31-2025
- Dividend Yield
- VSTM N/A
- ONCY N/A
- EPS Growth
- VSTM N/A
- ONCY N/A
- EPS
- VSTM N/A
- ONCY N/A
- Revenue
- VSTM $10,000,000.00
- ONCY N/A
- Revenue This Year
- VSTM $129.06
- ONCY N/A
- Revenue Next Year
- VSTM $306.32
- ONCY N/A
- P/E Ratio
- VSTM N/A
- ONCY N/A
- Revenue Growth
- VSTM N/A
- ONCY N/A
- 52 Week Low
- VSTM $2.10
- ONCY $0.33
- 52 Week High
- VSTM $9.10
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- VSTM 40.44
- ONCY 71.44
- Support Level
- VSTM $4.01
- ONCY $0.56
- Resistance Level
- VSTM $6.62
- ONCY $0.81
- Average True Range (ATR)
- VSTM 0.34
- ONCY 0.08
- MACD
- VSTM -0.03
- ONCY 0.02
- Stochastic Oscillator
- VSTM 42.00
- ONCY 92.97
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.